BMS’ Plaque Psoriasis Drug Deucravacitinib Among Six Hopefuls Awaiting EMA Verdict

 
• By Vibha Sharma

A novel TYK2 inhibitor and a drug to treat an ultra-rare genetic disorder are among products up for a marketing authorization opinion this week from the European Medicines Agency’s human medicines committee, the CHMP.

Concept of EMA European Medicines Agency. Drugs evaluation and quality control.
Companies Could Soon Learn If Their Products Have Won The EMA’s Backing • Source: Shutterstock

More from Approvals

More from Product Reviews